Pfizer's Lipitor reduced hospitalization costs 21% during trial

03/27/2007 | Forbes

Pfizer cites a recent analysis of an open-label trial of 8,888 patients in announcing its Lipitor, the leading cholesterol drug, reduces the risk of heart problems and hospital costs. The risk reduction in patients with heart disease led to a 21% decrease in hospitalization costs during the five years of the study when compared with simvastatin.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX